Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umbilical cord-derived MSCs to prevent chronic GVHD after HLA-haploidentical HSCT
ChiCTR-IIR-16007806Phase 2Completed
- Sponsor
- Xinqiao Hospital
- Start
- Apr 2016
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of human umbilical cord mesenchymal stem cells in hematopoietic malignancies and graft-versus-host disease (GVHD) (2 arms), sponsored by Xinqiao Hospital. Primary endpoint: Incidence of severe chronic graft-versus-host disease. Started Apr 2016; status: completed.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
hematopoietic malignanciesgraft-versus-host disease (GVHD)
Beyond the preview
Go deeper on ChiCTR-IIR-16007806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-16007806.